Former President and COO · Jazz Pharmaceuticals plc (JAZZ)

Daniel Swisher

A named executive officer of Jazz Pharmaceuticals in every fiscal year CompBrief holds from FY2018 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$5,528,973

Salary $834,869Stock awards $4,093,987

FY2019: $4,707,407

2nd of 7 named executive officers at Jazz Pharmaceuticals by FY2023 total.

7 named officers on file for Jazz Pharmaceuticals, FY2023

Daniel Swisher’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 8 equity grants, each cited to its filing
  • JAZZ’s disclosed peer group of 13 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Jazz Pharmaceuticals’s whole pay program stands against its peers

  • Jazz Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on JAZZ→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 14, 2024 (DEF 14A).

Free

Get Daniel Swisher’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Daniel Swisher compensation by year

Jazz Pharmaceuticals Summary Compensation Table · all 3 fiscal years held
In US dollars, as Jazz Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2023
Salary$608,173$667,308$834,869
Bonus$125,000$0$0
Stock awards$2,532,058$1,960,419$4,093,987
Option awards$2,075,162$1,506,379$0
Non-equity incentive$400,000$560,000$570,000
Pension and deferred compensation$0$0$0
All other$12,948$13,302$30,118
Total$5,753,341$4,707,407$5,528,973

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Jazz Pharmaceuticals plc DEF 14A filed June 14, 2024, accession 0001232524-24-000049, and prior-year filings.

How this page was built: the Jazz Pharmaceuticals plc filed document, accession 0001232524-24-000049. Every figure is read from that document and cited to the page and table it appears in. Filed June 14, 2024.

$5.8M
$4.7M
$5.5M
FY18
FY19
FY23
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
PSU13,507$1,661,361—
RSU13,456$1,655,088—
PSU13,456$1,655,088—
RSU10,130$1,245,990—
RSU7,949$977,727—
RSU5,556$683,388—
RSU3,333$409,959—
Option1,385—$113.10

Per the Outstanding Equity Awards at Fiscal Year-End table in Jazz Pharmaceuticals plc's FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Jazz Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Bruce CozaddChairman and Chief Executive Officer$15,341,235
Daniel Swisher · this pageFormer President and COO$5,528,973
Renée GaláPresident and COO$5,434,388
Robert IannoneExecutive Vice President, Research and Development and Chief Medical Officer$4,979,077
Kim SablichFormer Executive Vice President and General Manager, US$4,165,304
Neena PatilExecutive Vice President and Chief Legal Officer$3,877,435
Patricia CarrSenior Vice President and Chief Accounting Officer (Former Interim Principal Financial Officer)$1,401,028

The full Jazz Pharmaceuticals compensation record

free company brief

This page is one person within Jazz Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Jazz Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Jazz Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Daniel Swisher's compensation dossier · One-time report. No refunds.